Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GB18 in Healthy Adults
NCT07237464Phase 1Recruiting
- Sponsor
- Kexing Biopharm
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GB18-06 in cancer cachexia (10 cohorts), sponsored by Kexing Biopharm. Primary endpoint: Number of adverse events as assessed by CTCAE v5.0 at 18 weeks. Started Oct 2025; status: recruiting.
02
Drugs
GB18-06
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT07237464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07237464.